PPTI公司开发出防止泄漏的外科密封剂

一种新型外科密封剂设计用于防止肺脏、胃肠道、以及心血管外科手术后气体和液体的泄漏。

手术后的气体和液体泄漏是一种常见并发症，经常导致进一步的手术。新型密封剂应用于手术缝合或者留管处周围的组织。使用简单的双重注射器将密封剂喷雾到切口处。在不到一分钟的时间内，一种坚固而有弹性的屏障即可形成，并紧紧黏附于需要修补的组织上。当组织愈合之后，密封剂就组建别吸收。这种密封剂是由Protein Polymer技术集团(PPTI, San Diego, CA, USA)研制开发的。

总执行官兼总裁Donald S.Kaplan说：“这种新产品的卓越表现我们公司核心组织黏附工艺商业持续不断开发的一个令人兴奋的里程碑。我们产品研制开发团队的成就清晰地证明了这种工艺广泛的应用前景。”

PPTI是蛋白质设计与合成方面的先锋，制造了许多获得的生物物质，用于开发具有生物活性的设备。这些基因工程改造的生物物质是高分子量的蛋白质，经过处理成为具有生理和生物特性的产品，用于定制满足特殊临床需求。
 
Surgical Sealant Prevents Leaks
 
A new surgical sealant is designed to prevent air and fluid leaks following lung, gastrointestinal, and cardiovascular surgery.

Air and fluid leaks following surgery are a common source of complications that often lead to further surgery. The new sealant is applied following closure of tissues with sutures or staples. The sealant is sprayed over the incision by a simple dual-syringe applicator. In less than a minute, a tough, flexible barrier is formed that strongly adheres to the tissue being repaired. As the tissue heals, the sealant gradually resorbs. The sealant was developed by Protein Polymer Technologies, Inc. (PPTI, San Diego, CA, USA).

“The performance demonstrated with this new product is an exciting milestone in the continuing commercial development of our core tissue adhesive technology,” said Donald S. Kaplan, Ph.D., president and chief operating officer. “The accomplishments of our product development team clearly demonstrate the breadth of capabilities of this technology.”

PPTI has been a pioneer in protein design and synthesis, creating an extensive portfolio of proprietary biomaterials for use in the development of bioactive devices. These genetically engineered biomaterials are high-molecular-weight proteins, processed into products with physical and biologic characteristics tailored to specific clinical performance requirements.